Affordable Access

Physostigmine ameliorates the delusions of Alzheimer's disease.

Authors
  • Cummings, J L
  • Gorman, D G
  • Shapira, J
Type
Published Article
Journal
Biological Psychiatry
Publisher
Elsevier
Publication Date
Apr 01, 1993
Volume
33
Issue
7
Pages
536–541
Identifiers
PMID: 8513039
Source
Medline
License
Unknown

Abstract

Alzheimer's disease (AD) patients frequently manifest delusions, and the cholinergic deficiency of AD may contribute to this aspect of the psychopathology of the disorder. In a double-blind, crossover study involving two patients, we compared the antidelusional efficacy of physostigmine, an acetylcholinesterase inhibitor, with haloperidol, a widely used neuroleptic agent. Physostigmine ameliorated the delusions and produced fewer side effects. These preliminary observations suggest that the cholinergic deficiency contributes to the occurrence of delusions in AD and cholinergic therapy may have a role in the treatment of the delusional symptoms.

Report this publication

Statistics

Seen <100 times